# Lysophosphatidylethanolamine Degradation Associated with Upregulation of Pnpla6/7 in a Murine Model of Metabolic Dysfunction-Associated Steatohepatitis

**Authors:** Nao Inoue, Hsin-Jung Ho, Siddabasave Gowda B. Gowda, Miki Eguchi, Minato Masamura-Takeuchi, Hitoshi Chiba, Shu-Ping Hui

PMC · DOI: 10.3390/ijms27041869 · International Journal of Molecular Sciences · 2026-02-15

## TL;DR

This study explores how LPE levels drop in a mouse model of fatty liver disease, linking it to increased Pnpla6/7 activity and liver inflammation.

## Contribution

The study identifies Pnpla6/7-driven LPE catabolism as a novel mechanism contributing to LPE depletion in MASH.

## Key findings

- HFCC/CDX mice showed reduced LPE levels in plasma and liver, correlating with liver inflammation.
- LPE degradation was linked to upregulated Pnpla6/7 in the liver of MASH mice.
- LPE depletion was associated with cholesterol and oxidized triglyceride accumulation in the liver.

## Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a form of fatty liver disease characterized by fat accumulation, hepatic inflammation, and fibrosis. Lysophosphatidylethanolamine (LPE), a partially deacylated product of phosphatidylethanolamine, plays significant roles in anti-inflammatory responses and mitochondrial homeostasis. Although serum LPE levels are reduced in patients with MASH, the underlying mechanisms remain unclear. In this study, we investigated LPE metabolism using liquid chromatography–tandem mass spectrometry and protein expressions in MASH mice. Male C57BL/6J mice were fed a high-fat, high-cholesterol, and cholic acid diet, along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC/CDX) for three weeks to induce MASH. LPE was primarily distributed in the liver and kidneys, with lower levels in the white adipose tissue. HFCC/CDX mice exhibited accumulation of cholesterols and oxidized triglycerides, accompanied by inflammation and fibrosis in the liver. In the plasma and liver of HFCC/CDX mice, most LPE species were decreased and showed negative correlations with hepatic inflammation, with the exception of LPE 18:1. Mechanistically, enhanced degradation of LPE to glycerophosphorylethanolamine was associated with upregulation of Pnpla6/7 in the liver. These findings suggest that Pnpla6/7-driven LPE catabolism is contributing to LPE depletion. This study provides a new perspective to understand the association between disrupted phospholipid metabolism and MASH pathogenesis.

## Linked entities

- **Genes:** PNPLA6 (patatin like domain 6, lysophospholipase) [NCBI Gene 10908], PNPLA7 (patatin like domain 7, lysophospholipase) [NCBI Gene 375775]
- **Chemicals:** Lysophosphatidylethanolamine (PubChem CID 73755142), cholesterol (PubChem CID 5997), glycerophosphorylethanolamine (PubChem CID 123874)
- **Diseases:** Metabolic dysfunction-associated steatohepatitis (MONDO:0007027), MASH (MONDO:0007027)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Lpcat3 (lysophosphatidylcholine acyltransferase 3) [NCBI Gene 14792] {aka C3f, Grcc3f, Lpcat, Lpeat, Lplat5, Lpsat}, Enpp2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) [NCBI Gene 18606] {aka ATX, E-NPP 2, Npps2, PD-Ialpha, Pdnp2, lysoPLD}, Pla2g6 (phospholipase A2, group VI) [NCBI Gene 53357] {aka PNPLA9, iPLA(2)beta, iPLA2, iPLA2beta}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Pnpla7 (patatin-like phospholipase domain containing 7) [NCBI Gene 241274] {aka E430013P11Rik, Nre}, Cdx1 (caudal type homeobox 1) [NCBI Gene 12590] {aka Cdx, Cdx-1}, Selenoi (selenoprotein I) [NCBI Gene 28042] {aka 4933402G07Rik, D5Wsu178e, Ept1, SELI, mKIAA1724}, Cept1 (choline/ethanolaminephosphotransferase 1) [NCBI Gene 99712] {aka 9930118K05Rik, mCEPT1}, Pnpla8 (patatin-like phospholipase domain containing 8) [NCBI Gene 67452] {aka 1200006O19Rik, Ipla2(gamma)}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Pnpla6 (patatin-like phospholipase domain containing 6) [NCBI Gene 50767] {aka MSws, Nte}, Pisd (phosphatidylserine decarboxylase) [NCBI Gene 320951] {aka 9030221M09Rik}
- **Diseases:** cirrhosis (MESH:D005355), gallbladder enlargement (MESH:D005705), obesity (MESH:D009765), injury to (MESH:D014947), Metabolic Dysfunction-Associated Steatohepatitis (MESH:D005234), hepatic inflammation (MESH:D007249), gait disturbance (MESH:D020233), MASLD (MESH:D008107), Hepatomegaly (MESH:D006529), mitochondrial injury (MESH:D028361), liver injury (MESH:D017093), pain (MESH:D010146), anterior hypopituitarism (MESH:D007018), hepatocellular injury (MESH:D056486), visual impairment (MESH:D014786), hepatic lipid (MESH:D011017), neurological disorders (MESH:D009461), fat (MESH:D004620), glucose intolerance (MESH:D018149), Metabolic Dysfunction (MESH:D008659), hepatocellular carcinoma (MESH:D006528), insulin resistance (MESH:D007333), overnutrition (MESH:D044343), hair anomalies (MESH:D006201)
- **Chemicals:** methanol (MESH:D000432), PE (MESH:C483858), BA (MESH:D001647), GPE (MESH:C002449), lysophosphatidylserine (MESH:C025059), Methionine (MESH:D008715), fat (MESH:D005223), lysophosphatidylinositol (MESH:C025449), CDX (-), hydroxypropyl-beta-cy-clodextrin (MESH:D000073738), paraffin (MESH:D010232), water (MESH:D014867), TGs (MESH:C026285), phospholipid (MESH:D010743), Lysophospholipids (MESH:D008246), Hematoxylin (MESH:D006416), Oil Red O (MESH:C011049), PUFA (MESH:D005231), Ammonium acetate (MESH:C018824), 2,6-di-tert-butyl-p-cresol (MESH:D002084), chloroform (MESH:D002725), isoflurane (MESH:D007530), LPE (MESH:C008301), Lipid (MESH:D008055), SDS (MESH:D012967), isopropanol (MESH:D019840), choline (MESH:D002794), DG (MESH:D004075), ethylenediaminetetraacetic acid (MESH:D004492), polyvinylidene difluoride (MESH:C024865), nitrogen (MESH:D009584), heparin sodium (MESH:D006493), lysophosphatidylglycerol (MESH:C026223), Eosin (MESH:D004801), LPC (MESH:D008244), Tween 20 (MESH:D011136), MUFA (MESH:D005229), cholic acid (MESH:D019826), PS (MESH:D010718), SFA (MESH:D005227), CDP-Etn (MESH:C006933), PC (MESH:D010713), acetonitrile (MESH:C032159), formalin (MESH:D005557), LPA (MESH:C032881), Glucose (MESH:D005947), TG (MESH:D014280), Cholesterol (MESH:D002784), CE (MESH:D002788)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Leucotrichiinae sp. PE (species) [taxon 1840460], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940594/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940594/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940594/full.md

---
Source: https://tomesphere.com/paper/PMC12940594